Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 8412345...102030...Last »

Smoking tied to higher risk of hearing loss

Smokers may be more likely to develop hearing loss than nonsmokers, and the risk increases with each additional cigarette people smoke on a typical day, a Japanese study suggests.

Read More »

Auris Medical Fails Again in Phase III Trial

Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.

Read More »

AbbVie’s Elagolix Dazzles in Phase III Trial

AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.

Read More »

Newer gout drug poses risk to heart patients

Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.

Read More »

Improved Pressure-ulcer Outcomes with Wearable Technology

In the past few years, personal fitness trackers have become all the rage. It’s fun to see your daily activity level, sleep quality and heart rate. But, does knowing this data lead to any positive changes?

Read More »

Realm Therapeutics Conjunctivitis Drug Fails Phase II Trial

Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.

Read More »

Anthera’s lead drug fails study, shares slump

Anthera Pharmaceuticals Inc. is evaluating all strategic options after the company’s lead drug failed in a late-stage trial, sending shares down 80 percent in premarket trading.

Read More »

AstraZeneca lung cancer trial results pushed back

AstraZeneca expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half.

Read More »

MyoKardia Reports Positive Results in Heart Study

Shares of MyoKardia climbed after the company revealed positive results from a mid-stage clinical trial for obstructive hypertrophic cardiomyopathy.

Read More »

Sanofi, Evotec team up for research plarform

Sanofi and Evotec started exclusive talks over accelerating research into the treatment of infectious diseases and will form a new open innovation platform in this area, led by Evotec.

Read More »

Eisai, Merck Enter Strategic Oncology Collaboration

Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.

Read More »

Esperion cholesterol drug succeeds in late-stage study

Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

Read More »

Hetlioz Shows Promise for Treating Jet Lag

Vanda Pharmaceuticals, Inc., based in Washington, D.C., announced positive results from its JET8 Phase III clinical trial of Hetlioz for jet lag disorder.

Read More »

Dermira to abandon acne drug, shares crater

Dermira Inc. will discontinue development of the company’s acne drug after the experimental treatment failed to meet the main goals of two late-stage studies.

Read More »

Clearside Biomedical’s eye treatment succeeds study

Clearside Biomedical Inc. said the drug developer’s treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study.

Read More »

Santhera drug shows no efficacy benefit in MS study

Santhera Pharmaceuticals said a study of the Swiss drug company’s medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression.

Read More »

Ionis, Roche Tout Positive HD Trial Data

Roche and Ionis Pharmaceuticals touted biomarker data from an early-stage study that showed IONIS-HTTRx lowered the disease-causing protein in people with Huntington’s disease.

Read More »

DBV Reports Positive Data from Milk Allergy Trial

French company DBV Technologies said its Viaskin Milk product yielded successful results in a Phase II trial for patients suffering from IgE-mediated cow’s milk protein allergy.

Read More »

Bystander defibrillator use tied to better cardiac arrest outcomes

Cardiac arrest patients may be more likely to survive and avoid permanent disabilities when bystanders use a defibrillator to treat them before an ambulance arrives, a new study suggests.

Read More »

Trulicity Combo Shows Improved Blood Sugar Control

Eli Lilly published results from a new Phase IIIb study of Trulicity (dulaglutide) in combination with a SGLT-2 inhibitor showing improved blood sugar control in adults with type 2 diabetes.

Read More »

Page 1 of 8412345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation